JP2017504324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504324A5 JP2017504324A5 JP2016544613A JP2016544613A JP2017504324A5 JP 2017504324 A5 JP2017504324 A5 JP 2017504324A5 JP 2016544613 A JP2016544613 A JP 2016544613A JP 2016544613 A JP2016544613 A JP 2016544613A JP 2017504324 A5 JP2017504324 A5 JP 2017504324A5
- Authority
- JP
- Japan
- Prior art keywords
- neoepitope
- subject
- cancer
- antigen
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 18
- 230000037439 somatic mutation Effects 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 238000002619 cancer immunotherapy Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000007482 whole exome sequencing Methods 0.000 claims description 3
- 239000012678 infectious agent Substances 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 16
- 230000004044 response Effects 0.000 description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 7
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 6
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 6
- 102100038078 CD276 antigen Human genes 0.000 description 6
- 101710185679 CD276 antigen Proteins 0.000 description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- 108010043610 KIR Receptors Proteins 0.000 description 6
- 102000002698 KIR Receptors Human genes 0.000 description 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 6
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 6
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 102100028749 Neuritin Human genes 0.000 description 3
- 101710189685 Neuritin Proteins 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923183P | 2014-01-02 | 2014-01-02 | |
| US61/923,183 | 2014-01-02 | ||
| US201462066034P | 2014-10-20 | 2014-10-20 | |
| US62/066,034 | 2014-10-20 | ||
| US201462072893P | 2014-10-30 | 2014-10-30 | |
| US62/072,893 | 2014-10-30 | ||
| PCT/US2014/072125 WO2015103037A2 (en) | 2014-01-02 | 2014-12-23 | Determinants of cancer response to immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017504324A JP2017504324A (ja) | 2017-02-09 |
| JP2017504324A5 true JP2017504324A5 (enExample) | 2018-02-08 |
Family
ID=53494217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544613A Pending JP2017504324A (ja) | 2014-01-02 | 2014-12-23 | 免疫療法に対する癌応答の決定因子 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160326597A1 (enExample) |
| EP (1) | EP3090066A4 (enExample) |
| JP (1) | JP2017504324A (enExample) |
| KR (1) | KR20160102314A (enExample) |
| CN (1) | CN106164289A (enExample) |
| AU (1) | AU2014374020A1 (enExample) |
| BR (1) | BR112016015399A2 (enExample) |
| CA (1) | CA2935214A1 (enExample) |
| CL (1) | CL2016001708A1 (enExample) |
| MX (1) | MX2016008771A (enExample) |
| PE (1) | PE20161344A1 (enExample) |
| PH (1) | PH12016501329A1 (enExample) |
| RU (1) | RU2707530C2 (enExample) |
| SG (2) | SG11201605432RA (enExample) |
| WO (1) | WO2015103037A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| CA2966660A1 (en) | 2014-11-13 | 2016-05-19 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| IL293135A (en) | 2015-05-13 | 2022-07-01 | Agenus Inc | Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| US11623001B2 (en) * | 2015-10-12 | 2023-04-11 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| JP2018532736A (ja) * | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
| MX387275B (es) * | 2015-10-12 | 2025-03-18 | Nantomics Llc | Neoepítopos virales y sus usos |
| JP6938489B2 (ja) * | 2015-10-23 | 2021-09-22 | ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ | 視野に存在する選択された細胞のバイオマーカー陽性率の値を導き出す方法 |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| EP3400005A1 (en) * | 2016-01-08 | 2018-11-14 | Vaccibody AS | Neoepitope rna cancer vaccine |
| EP3417289B1 (en) | 2016-02-19 | 2020-12-23 | Nant Holdings IP, LLC | Methods of immunogenic modulation |
| CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| JP2019509282A (ja) | 2016-02-29 | 2019-04-04 | ファウンデーション・メディシン・インコーポレイテッド | 癌の治療方法 |
| WO2017159686A1 (ja) * | 2016-03-15 | 2017-09-21 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 |
| RU2769314C1 (ru) * | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| WO2017214575A1 (en) * | 2016-06-10 | 2017-12-14 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| US20190247435A1 (en) * | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| US11332530B2 (en) | 2016-09-23 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| CA3038712A1 (en) * | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| CN110214275B (zh) | 2016-12-01 | 2022-12-06 | 南托米克斯有限责任公司 | 肿瘤抗原性加工和呈递 |
| WO2018112449A2 (en) | 2016-12-16 | 2018-06-21 | Nant Holdings Ip, Llc | Live cell imaging systems and methods to validate triggering of immune response |
| WO2018132753A1 (en) * | 2017-01-13 | 2018-07-19 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| US12331359B2 (en) | 2017-01-18 | 2025-06-17 | Michael Laessig | Neoantigens and uses thereof for treating cancer |
| WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
| JP2020511137A (ja) * | 2017-03-17 | 2020-04-16 | ナントミクス，エルエルシー | ｃｆＲＮＡに関する液体生検 |
| KR20250036268A (ko) * | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP3933408A1 (en) | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| US20180357361A1 (en) * | 2017-06-13 | 2018-12-13 | Feliks Frenkel | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| RU2020113600A (ru) | 2017-09-20 | 2021-10-20 | Ридженерон Фармасьютикалз, Инк. | Способы иммунотерапии пациентов, опухоли которых характеризуются высокой нагрузкой пассажирскими генными мутациями |
| CN111432837A (zh) * | 2017-09-25 | 2020-07-17 | 纪念斯隆凯特琳癌症中心 | 肿瘤突变负荷和检查点免疫疗法 |
| EP3688165A4 (en) | 2017-09-25 | 2021-09-29 | Nant Holdings IP, LLC | VALIDATION OF THE PRESENTATION OF NEOEPITOPES |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| EP3704268B1 (en) | 2017-11-03 | 2025-01-22 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| CN111566484A (zh) * | 2017-11-09 | 2020-08-21 | 宾夕法尼亚大学董事会 | 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途 |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| WO2019109086A1 (en) * | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| CN108009400B (zh) * | 2018-01-11 | 2018-07-06 | 至本医疗科技（上海）有限公司 | 全基因组肿瘤突变负荷预测方法、设备以及存储介质 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| CN120193081A (zh) | 2018-07-23 | 2025-06-24 | 夸登特健康公司 | 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统 |
| AU2019328344B2 (en) | 2018-08-31 | 2025-06-12 | Guardant Health, Inc. | Microsatellite instability detection in cell-free DNA |
| CN109371005B (zh) * | 2018-11-12 | 2022-09-30 | 上海市东方医院（同济大学附属东方医院） | 一种hla-0201限制性padi4表位多肽及其应用 |
| WO2020121226A1 (en) * | 2018-12-12 | 2020-06-18 | Medimmune, Llc | Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer |
| SG11202106708VA (en) * | 2018-12-21 | 2021-07-29 | Agency Science Tech & Res | Method of predicting for benefit from immune checkpoint inhibition therapy |
| CA3104293A1 (en) | 2019-04-05 | 2020-10-08 | Illumina, Inc. | Quantitative score of hla diversity |
| US20200371103A1 (en) * | 2019-05-24 | 2020-11-26 | Iuve, Inc. | Precision Medicine Method for Cancer Immunotherapy |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
| CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4000595A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| EP4000596A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| US20240192195A1 (en) * | 2021-04-10 | 2024-06-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024216165A1 (en) | 2023-04-12 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Computational methods for selecting personalized neoantigen vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| CA2585776A1 (en) * | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| KR102315754B1 (ko) * | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/ko not_active Withdrawn
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/es unknown
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/es unknown
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/ru not_active IP Right Cessation
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/zh active Pending
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/pt not_active IP Right Cessation
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/ja active Pending
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en not_active Ceased
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/es unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504324A5 (enExample) | ||
| Chiou et al. | Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery | |
| RU2016131207A (ru) | Детерминанты ответа раковой опухоли на иммунотерапию | |
| Khodadoust et al. | Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens | |
| Fehlings et al. | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment | |
| Yang et al. | Advancing CAR T cell therapy through the use of multidimensional omics data | |
| Bear et al. | Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting | |
| JP7430136B2 (ja) | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 | |
| JP2018502828A5 (enExample) | ||
| CN113474840B (zh) | 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统 | |
| Topalian et al. | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | |
| WO2016081947A4 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| Bauer et al. | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma | |
| JP7073254B2 (ja) | 癌における「免疫チェックポイント介入」 | |
| JP2023159353A (ja) | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 | |
| Chen et al. | Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma | |
| Kiyotani et al. | Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens | |
| Hammerl et al. | Adoptive T cell therapy: new avenues leading to safe targets and powerful allies | |
| JP2022520230A (ja) | 抗原特異的ｔ細胞の同定のための組成物と方法 | |
| Verma et al. | Immunotherapy in extensive small cell lung cancer | |
| JP2014530009A5 (enExample) | ||
| JP2018524973A5 (enExample) | ||
| US11821027B2 (en) | Epigenetic analysis of cell therapy and related methods | |
| Choudhury et al. | Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies | |
| Zappasodi et al. | Strategies for predicting response to checkpoint inhibitors |